Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
L. Yang, T. M. Caradonna, A. Schmidt, A. K. Chakraborty
The paper develops a computational model to study antibody evolution after vaccination with designed influenza immunogens, finding that a chimeric antigen outperforms a cocktail in eliciting RBS-directed antibodies due to T cell interactions.
bioRxiv · Dec 2, 2022Immunology
T. M. Caradonna, I. W. Windsor, A. R. Roffler, S. Song, A. Watanabe, G. Kelsoe, M. Kuraoka, A. G. Schmidt
This study shows that an epitope-enriched immunogen preferentially expands RBS-directed antibody responses compared to non-enriched immunogens.
bioRxiv · Dec 1, 2022 · PreprintImmunology
F. Borriello, E. Nanishi, H.-S. Seo, T. R. OMeara, M. E. McGrath, Y. Saito, R. E. Haupt, J. Chen, J. Diray-Arce, K. Song, A. Z. Xu, T. M. Caradonna, J. Feldman, B. M. Hauser, A. G. Schmidt, , O. Levy
This study identifies an adjuvanted SARS-CoV-2 RBD nanoparticle that induces neutralizing antibodies and full protection in aged mice.
bioRxiv · Sep 9, 2021 · PreprintImmunology
E. Nanishi, F. Borriello, T. R. O'Meara, M. E. McGrath, Y. Saito, R. E. Haupt, H.-S. Seo, S. D. van Haren, B. Brook, J. Chen, J. Diray-Arce, S. Doss-Gollin, M. De Leon, K. Chew, M. Menon, , D. J. Dowling
This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.
bioRxiv · May 20, 2021Immunology
D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch
This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.
bioRxiv · Mar 22, 2021 · PreprintMicrobiology
D. Li, R. J. Edwards, K. Manne, D. R. Martinez, A. Schafer, S. M. Alam, K. Wiehe, X. Lu, R. Parks, L. L. Sutherland, T. H. Oguin, C. McDanal, L. G. Perez, K. Mansouri, S. M. C. Gobeil, , Petzol
This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.
bioRxiv · Dec 31, 2020 · PreprintImmunology
B. M. Hauser, M. Sangesland, E. C. Lam, K. J. St. Denis, J. Feldman, A. S. Yousif, T. M. Caradonna, T. Kannegieter, A. B. Balazs, D. Lingwood, A. G. Schmidt
This study shows that a cocktail of trimeric sarbecovirus receptor binding domains elicits broadly neutralizing antibodies against multiple sarbecoviruses, including in the context of prior SARS-CoV-2 immunity.
bioRxiv · Dec 7, 2020 · PreprintImmunology
A. Wellner, C. McMahon, M. S. A. Gilman, J. R. Clements, S. Clark, K. M. Nguyen, M. H. Ho, J.-E. Shin, J. Feldman, B. M. Hauser, T. M. Caradonna, L. M. Wingler, A. G. Schmidt, D. S. Marks, J. Abraham, , C. C. Liu
This paper introduces AHEAD, a yeast-based system for rapid antibody generation through autonomous hypermutation, achieving high-affinity antibodies against SARS-CoV-2 and other targets in just 2 weeks.
bioRxiv · Nov 11, 2020Bioengineering
T. M. Clausen, D. R. Sandoval, C. B. Spliid, J. Pihl, C. D. Painter, B. E. Thacker, C. A. Glass, A. Narayanan, S. A. Majowicz, Y. Zhang, J. L. Torres, G. J. Golden, R. Porell, A. F. Garretson, L. Laubach, , J. D. Esko
This study shows SARS-CoV-2 spike protein binds to heparan sulfate and ACE2 on cells codependently, forming a complex that facilitates infection, suggesting potential therapeutic targets.
Cell · Nov 1, 2020Peer-reviewedMicrobiology